Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Apr 18;25(1):273.
doi: 10.1186/s12876-025-03879-y.

Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication

Yi-Zhou Jiang  1 , Kai Ma  1 , Cheng Cui  1 , Zhuo-Ya Li  1 , Xiao-Yong Wang  2
Affiliations
Meta-Analysis

Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication

Yi-Zhou Jiang et al. BMC Gastroenterol. .

Abstract

Background: Helicobacter pylori (H. pylori) infection is a common chronic infection, and there are over half of the global population infected with H. pylori. It is still controversial whether the supplementation of Saccharomyces boulardii (S. boulardii) to bismuth quadruple therapy is beneficial for H. pylori eradication.

Aim: To determine the effects of S. boulardii supplementation to bismuth quadruple therapy on H. pylori eradication.

Methods: We performed a systematic literature search across PubMed, Embase, Web of Science, and China National Knowledge Infrastructure for articles published up to October 2023. We calculated the pooled relative risk (RR) with the 95% confidence interval (CI). Statistical analyses were conducted using Stata/SE 15.1 software.

Results: Ten randomized controlled trials were included. Notably, S. boulardii supplementation to bismuth quadruple therapy significantly improved H. pylori eradication rates (RR = 1.08, 95% CI: 1.04-1.12) and reduced the incidence of total adverse effects (RR = 0.53, 95% CI: 0.45-0.62). Specifically, it reduced the incidence of some gastrointestinal adverse effects and nonspecific adverse effects, including diarrhea (RR = 0.28, 95% CI: 0.22-0.36), constipation (RR = 0.32, 95% CI: 0.18-0.55), abdominal distention (RR = 0.39, 95% CI: 0.26-0.59), nausea (RR = 0.59, 95% CI: 0.36-0.97), and rash (RR = 0.49, 95% CI: 0.28-0.86). In the subgroup analysis, long-term eradication duration (> 10 days; RR = 1.08, 95% CI: 1.04-1.13) and S. boulardii supplementation to be started and stopped at the same time as eradication treatment (RR = 1.09, 95% CI: 1.04-1.14) were found to significantly improve the eradication rate regardless of the S. boulardii dose (500 mg/day, RR = 1.10, 95% CI: 1.03-1.17; 1000 mg/day, RR = 1.08, 95% CI: 1.03-1.12).

Conclusions: The addition of S. boulardii to bismuth quadruple therapy significantly increased H. pylori eradication rates and decreased the adverse effects. We recommend adding 500 mg/day S. boulardii concurrently with bismuth quadruple therapy and continuing this therapy for > 10 days for optimal H. pylori eradication efficacy.

Keywords: Saccharomyces boulardii; Bismuth quadruple therapy; Helicobacter pylori; Meta-analysis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not Applicable. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests. PRISMA 2009 checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

Figures

Fig. 1
Fig. 1
Flow chart depicting screening and selection procedures
Fig. 2
Fig. 2
Forest plot of H. pylori eradication rates for effects of S. boulardii supplementation
Fig. 3
Fig. 3
Forest plot for the effects of S. boulardii supplementation on total adverse effects
Fig. 4
Fig. 4
Funnel plot of the included studies. (a) Funnel plot of the eradication rates. (b) Funnel plot of the incidence of total adverse effects
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Crowe SE. Helicobacter pylori infection. New Engl J Med. 2019;380:1158–65. [PMID: 30893536 10.1056/NEJMcp1710945]. - PubMed
    1. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022. [PMID: 35944925 10.1136/gutjnl-2022-327745]. - PubMed
    1. Zhou L, Lu H, Song Z, Lyu B, Chen Y, Wang J, Xia J, Zhao Z. 2022 Chinese National clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J-Peking. 2022;135:2899–910. [PMID: 36579940 10.1097/CM9.0000000000002546]. - PMC - PubMed
    1. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: A systematic review and Meta-analysis in world health organization regions. Gastroenterology. 2018;155:1372-1382.e17. [PMID: 29990487 10.1053/j.gastro.2018.07.007]. - PMC - PubMed
    1. Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The ideal Helicobacter pylori treatment for the present and the future. Digestion. 2022;103:62–8. [PMID: 34662879 10.1159/000519413]. - PubMed

MeSH terms

LinkOut - more resources